GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ANIK · Dec 31, 2024

Anika Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001171843-25-001486General Corporate
Capex intensity88thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

6.45% · OPTIONAL · VALID

Operating cash generation75thOwn-history percentile · N=8
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

4.51% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

-28.05% · CORE · NOT_ENOUGH_HISTORY

Inventory pressure0thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

19.86% · OPTIONAL · VALID

Gross margin75thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.gross_margin

63.38% · CORE · VALID

Operating margin88thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.operating_margin

-4.25% · CORE · VALID

R&D intensity88thOwn-history percentile · N=8
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

21.30% · OPTIONAL · VALID

SBC intensity100thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

10.95% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History15 statesHistory building
Dec 31, 20220/7 normalizedLevel 3Mar 31, 20230/7 normalizedLevel 3Jun 30, 20230/7 normalizedLevel 3Sep 30, 20230/7 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/8 normalizedLevel 3Jun 30, 20240/8 normalizedLevel 3Sep 30, 20240/8 normalizedLevel 3Dec 31, 20247/8 normalizedLevel 3Mar 31, 20257/8 normalizedLevel 3Jun 30, 20257/8 normalizedLevel 3Sep 30, 20256/7 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 3
Period transition

What moved in the state?

Capex Intensity Increased
Previous
3.14%
Current
6.45%
Delta
3.31%
Cash Generation Decreased
Previous
12.94%
Current
4.51%
Delta
-8.44%
Growth Decreased
Previous
-6.54%
Current
-28.05%
Delta
-21.51%
Inventory Pressure Decreased
Previous
102.26%
Current
19.86%
Delta
-82.40%
Margin Increased
Previous
3.72%
Current
63.38%
Delta
59.66%
Profitability Increased
Previous
-72.30%
Current
-4.25%
Delta
68.04%
R And D Intensity Increased
Previous
18.69%
Current
21.30%
Delta
2.61%
Sbc Intensity Increased
Previous
8.76%
Current
10.95%
Delta
2.19%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · ANIK Fundamental State →Has State · Anika Therapeutics, Inc. →Transitioned To · ANIK Fundamental State →Transitioned To · ANIK CAPEX_INTENSITY_INCREASED →Transitioned To · ANIK CASH_GENERATION_DECREASED →Transitioned To · ANIK GROWTH_DECREASED →Transitioned To · ANIK INVENTORY_PRESSURE_DECREASED →Transitioned To · ANIK MARGIN_INCREASED →Transitioned To · ANIK PROFITABILITY_INCREASED →Transitioned To · ANIK R_AND_D_INTENSITY_INCREASED →Transitioned To · ANIK SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.